Labiotech.eu’s Post

The reality of today’s precision medicine is only 10% of cancer patients experience a clinical benefit from treatments matched to tumor DNA mutations (via biomarker testing). OncoDxRx's mission is to build a personalized guide of the most effective drugs for every cancer patient. OncoDxRx’s one-of-a-kind PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) works by testing tumor gene activities from a patient’s own blood before administering treatment, tailoring therapies that are most likely to benefit the patient while minimizing waiting time, cost and ineffective drugs. Other than DNA mutations, PGA takes a different approach to personalizing treatments. The technology takes a sample of a patient’s blood, analyzes patient-unique gene expression signature, searches and maps over 700 drugs (approved, investigational or in clinical trials). In this process, the scientists look for the medications that the patient has a high likelihood to respond to. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Big confluence of factors driving an ever bigger market opportunity. The War on Cancer will never end, and never not keep attracting outsized investment up and down the stack. "The market is primarily driven by factors such as an increase in technological advancements, a rise in cancer incidences, and improvements in personalized medicine and cell and gene therapies, which are starting new approaches for developing new treatments for cancer-like diseases. Moreover, an increase in funding from pharmaceutical and biotech companies, non-profit organizations, and CROs for oncology clinical trials is further supporting market growth and the development of advanced products to gain substantial market share." #5ForcesofHCT #Pharma #Cancer #ClinicalTrials #Biotech #Biopharma https://lnkd.in/gTEyCcUz

🔎𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 Evox Therapeutics Ltd Targets protein misfolding in diseases like Alzheimer's and cancer. Sana Biotechnology, Inc. Uses gene editing for curative cell therapies in blood diseases. Ikena Oncology Targets unique metabolic pathways in hard-to-treat cancers. Pionyr Immunotherapeutics Develops next-gen immunotherapies to supercharge a patient's immune system against cancer. BlueWillow Biologics, Inc. Pioneering a new approach to target RNA for treating neurodegenerative diseases like ALS. Absci Uses AI to speed up drug discovery, leading to faster development of new treatments. Let me know in the comments any other biotech's to watch out for 👇🏼 #biotech #research #drugdevelopment #drugdiscovery

Seven molecular glue startups looking to stick around in the biotech industry: Since molecular glues were discovered three decades ago, they have become a therapeutic option for treating several difference disease areas, including cancer and neurodegenerative disorders. Molecular glue refers to a small molecule that sticks two proteins together. These molecules were originally discovered by chance, but more recently scientists have been able to design them into a class of medicines, known as targeted protein degraders, destroying disease-causing proteins. Therefore, molecular glues are the newest promising solution to attacking targets that were previously labelled as ‘undruggable’. Now, there are a rising number of molecular glue companies hoping to show clinical success with their candidates. Discover more about these new therapeutics: #therapeutics #molecularbiology #lifesciences

Situational awareness and drug response prediction in cancer treatment is critical to maintaining the therapeutic advantage. Yet the increasing heterogeneity of tumor is constantly challenging this advantage. The evolving of drug resistance, in particular targeted therapy, is significantly contributing to shifting cancer battlefield supremacy. High proliferation and the constant evolution of tumor clones in terms of dynamics, kinetics, immunoediting, immunosuppression and immune escaping increases the level of cancer threat day by day. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing

Using PGA to identify potent and selective drugs for the treatment of cancer Across the world, cancer poses serious threats to everyone’s health, and overall quality of life. In order to identify potential effective drugs for new therapeutics, the research team at OncoDxRx leveraged its proprietary gene expression-driven drug identification platform, PGA, to facilitate clinical decision-making on three types of cancers, including lung, pancreatic, and breast cancer. Using cell-free mRNA based gene expression signature strategies and applying rigorous filters for similarity and selectivity, OncoDxRx scientists identified an array of existing drugs which the patient is likely to respond to. This knowledge provided clinical guidance for treatment strategy optimization, leading to better patient outcome. The innovative PGA test has not only presented a breakthrough for effective drug identification but has also led to the revolution of drug repurposing. PGA expands OncoDxRx’s one-of-a-kind liquid biopsy pipelines and paves the way toward a safer, more effective therapeutic future for patients battling lung, pancreatic, and breast cancers. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Since they were discovered around three decades ago, molecular glues - also known as targeted protein degraders - have come a very long way as a therapeutic option for several different disease areas 🧬🔍 - from cancer to neurodegenerative disorders. 🧠 These small molecules - which ‘stick’ two proteins together 🧩 - are now seen as extremely promising solutions to potentially attack targets that were previously considered ‘undruggable’. As a result, there is also a rising number of molecular glue startups hoping to show clinical success with their candidates 🚀, with the targeted protein degradation market size poised to grow from $113.85 million in 2022, to $247.61 million by 2030. 📈 Check out our latest article to discover seven of the startups that are aiming to make it big in the field of molecular glues! 👇 https://lnkd.in/d2z3arfn C4 Therapeutics, Inc. | Degron Therapeutics | Magnet Biomedicine | Monte Rosa Therapeutics | Orionis Biosciences | Proxygen | TRIANA Biomedicines #Biotech #MolecularGlues #CancerResearch #ProteinDegradation #ProteinDegraders #BiotechStartups #NeurodegenerativeDisorders #BiotechIndustry

#biotech fundraisings of the week: Deals in the U.S. are slowing down after 3 crazy weeks, Europe is still registering a good number of deals 👇 🇺🇸BridgeBio | $250 million Private Placement Equity | precision medicine and gene therapy | phase 3 in transthyretin amyloidosis and autosomal dominant hypocalcemia type 1 🇩🇰Acesion Pharma | €45M ($47.56 million) Series B | cardiac disease therapies | phase 2 in cardiac arrhythmia 🇬🇧Sitryx | $39 million Venture round | immunometabolism-targeting therapies | preclinical in multiple sclerosis 🇨🇭TOLREMO therapeutics | $39 million Series A | cancer therapies | Preclinical in targeting cancer drug resistance 🇩🇰Notify Therapeutics | €5 million ($5.32 million) Seed round | non-hormonal fertility treatment | proof of concept targeting infertility 🇬🇧Crucible Therapeutics | £5 million (£6.07 million) Seed round | gene therapies | preclinical in motor neurone disease and frontotemporal dementia Want to keep track of biotech fundraising? Sign up to Labiotech.eu's newsletter!

One of OncoDxRx strengths is that we master liquid biopsy technologies of molecular theranostics. We obtain our information directly from patients, from the operations we conduct in the lab, from our network of databases, and from our in silico data analytics. These channels integrate and complement one another at the very heart of OncoDxRx. This feature provides us with high-accuracy tests and gives us the edge as a leader of innovation. OncoDxRx’s strategy is the global commercialization of disruptive and exclusive technologies in cancer theranostics, extending people’s lives, improving the survival of cancer patients and helping them to avoid unnecessary and ineffective treatments, while reducing healthcare burdens. To this end, OncoDxRx has invented and developed one-of-it’s-kind revolutionary tests such as PGA (Patient-derived Gene expression-informed Anticancer drug efficacy), OncoMRD (OncoDxRx’s molecular residual disease) and OncoMCED (OncoDxRx’s multi-cancer early detection) for next-generation cancer management. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

🔍 Exciting news in biotech investments! These investments show the growing potential in biometrics. Great to see advancements across different health areas, from mental health to cancer treatment 🇺🇸 Spyre Therapeutics | $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease 🇺🇸 Engrail Therapeutics | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder 🇨🇦 Cybin Inc | $150 million PIPE | mental healthcare | phase 2 in major depressive disorder 🇩🇪 Tubulis GmbH | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors 🇺🇸 Unicycive Therapeutics | $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia 🇬🇧 Relation | $35 million seed | multi omics for drug discovery | discovery in osteoporosis 🇸🇪 Asgard Therapeutics | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer 🇬🇧 Mission Therapeutics | £25.2 million ($32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury 🇺🇸 Elicio Therapeutics | $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma